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Summary
Two patients with leukocyte adhesion deficiency (LAD), one with a moderate phenotype (patient
14) and one with a severe phenotype (patient 2) who had been shown to have a normal sized
a subunit protein precursor, were analyzed in an attempt to determine the molecular basis for
their disease. RNase mapping located possible mutations to two distinct but adjacent regions
of the 0 subunit cDNA. Sequencing of patient-derived cDNA clones in this region revealed
a C for T difference at amino acid 149 in patient 14 which resulted in the substitution of a
leucine for a proline, and an A for G substitution at amino acid 169 in patient 2 which mutated
a glycine to an arginine. The mutated amino acids are in a region of the cDNA that is highly
conserved between the fl subunits of the integrin family and are identical in all known integrin
a subunits. Co-transfection of the a subunit cDNA containing the patient 2 mutation with
the wild-type a subunit of LFA-1 in a mammalian expression system resulted in no expression
of LFA-1. In the case of the mutation in patient 14 there was markedly diminished expression
of LFA-1 with loss of function and loss of the epitope for a number of anti-)3 mAbs. Normal
half-life of the mutant 0 subunits, and previous demonstration of a lack of a/O complex formation
during biosynthesis in patient cells, suggest a defect in association with the a subunit. Association
with0 is required for expression of the a subunit of LFA-1. Loss of functional expression with
both of these 0 subunit mutations suggests that they lie in a site critical for association with
the a subunit.
T eukocyte adhesion deficiency (LAD)' is a rare, inherited,
jjautosomal recessive, immunodeficiency disease caused by
the combined loss ofexpression on the surface of leukocytes
ofthe leukocyte integrins LFA1, Mac-1, and p150,95 (reviewed
in reference 1). The disease is characterized by a marked
granulocytosis, lack of neutrophil and monocyte mobiliza-
tion to inflammatory sitesas seen in biopsies and manifested
in lack of pus formation, severe gingivitis and recurrent or
progressive necrotic soft tissue infections. About 30 patients
have so far been described with the disease. Based on degree
of expression the disease was subdivided into severe (<1%
expression) and moderate (3-10% expression) phenotypes (2).
Degree of expression correlated with the clinical severity of
the disease and the impairment of a number of in vitro im-
mune functions such as granulocyte adhesion and chemotaxis
and antibody-dependent cytotoxicity. Patients with the se-
vere form ofthe disease tend to succumb early in life to over-
whelming infection, whereas those with a moderate form
of the disease often survive through to adulthood.
The three leukocyte integrins are noncovalently linked het-
'Abbreviation used in this paper." LAD, leukocyte adhesion deficiency.
erodimers composed of a common fl subunit (CD18) and
homologous a subunits (LFA-la, CD11a; Mac-1a, CD11b;
p150,95a, CD11c) (3). They play a key role in a wide range
ofimmune functions (reviewed in reference 4). They are part
of a family of related receptors termed the integrins (4-6).
Three integrin subfamilies are defined by distinct a subunits
that can associate with multiple a subunits. The CD11/CD18
family is otherwise known as the leukocyte or ,82 integrin
family. The leukocyte integrins mediate cell-cell adhesion by
binding to counter-receptors on other cells. The adhesion
receptor LFA1 binds to the counter-receptors ICAM-1 and
ICAM-2 (7, 8). ICAM-1 expression is strongly induced in
tissues by inflammatory stimuli (9). Avidity of LFA-1 for
ICAM-1 is transiently increased by TCR stimulation and this
is mimicked by phorbol esters (10). The al and a3 families
are primarily receptors for extracellular matrix proteins (11).
The ail (VLA) family includes the fibronectin receptor (12)
and receptors for collagen and laminin (13, 14). The (33 family
includes the vitronectin receptor and the platelet glycopro-
tein IIb/IIIa (15). 132 shares 45% overall identity with (31
and 37% with f3 (16-19). There is, however, a highly con-
served region in the extracellular domain of 241 amino acids
in which the three f3 subunits are 65% identical. Contained
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protein IIb/IIIa (20).
Several lines of evidence have indicated that the defect in
LADis in the common (3 subunitof theleukocyteintegrins.
Allthe patients so far describedhave loss of each of thethree
leukocyteintegrins. In mouse/human lymphocyte hybrids it
was possible to recover expression of the human a subunit
of LFA-1 in combination with the mouse/3 subunit; recovery
of the human /3 subunit in combination with the mouse a
subunit was seen in hybrids with healthy but not with pa-
tient cells(21). Biosynthetic studies ofthe a subunit ofLFA1
in patientEBVtransformed B cells demonstrated that appar-
ently normal synthesis of the LFA1 a subunit occurred in
LADpatients but that it failed to be processed to the mature
form and was degraded withoutbeingexpressed (22). Simi-
larly using a rabbit antisera against the /3 subunit and a (3
subunit cDNA probe it was demonstrated that in a number
ofLADpatients theasubunitprecursorwas made in normal
amounts butlike the a subunit was degraded (23, 24). Studies
of mRNA expression and biosynthesis of the R subunit in
six unrelated patients and a family of four patients revealed
five patterns of abnormality (24). Definitive evidence for a
defect in thea subunit was found in two patients that had
no mRNA or protein precursor, one patient that had trace
mRNA andprotein, andafamily ofpatients that had a small
protein precursor. One patient had a large precursor, prob-
ably due to an extra glycosylation site, and two patients had
grossly normal mRNA expression and (3 subunit protein
precursor. Whether these patients had point mutations in
thea subunit was not determined. Heterogeneity in the de-
fect has also been reported in a group of patients in France
(25) . Thedefect in thefamily with thesmallproteinprecursor
was due to a single base pair substitution which resulted in
aberrant splicing and the deletion of a 90-bp exon in 95%
of the mRNA (26). The 5% of normally spliced mRNA
allowed some expression of normal protein on the cell sur-
face and explained the moderate phenotype in this kindred.
The molecular basis for LAD in patients who have a R
subunit precursor of normal size and amount is not known
and location of thedefect in the (3 subunit remains presump-
tive. If the defect is in the /3 subunit in these patients it is
likely to be subtle and due to a single amino acid substitu-
tion. Definition of the defect in these cases would help to
confirm that all forms of LAD are due to defects in the R
subunit as well as defining regions of the a subunit which
areof importance in associating with the asubunit. In addi-
tion it mayshed further lighton the reasonsforthedifferent
clinical phenotypes.
We therefore analyzed,by RNAsemapping, theRNA from
two patients, both ofwhom expressedgrosslynormal mRNA
and (3 subunit protein precursorbut who had different clin-
ical phenotypes. This revealed possible sites of mismatch in
the region highly conserved among integrin 0 subunits. Se-
quence analysis of cDNA clones from this region revealed
single amino acid substitutions in each of the two patients.
Both mutations caused defective expression and function of
the /3 subunit in COS cells.
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Materials and Methods
Monoclonal Antibodies. The mAbs T'S1/22 (LFA-1 a mAb,
IgG1), TS1/18 ((3 mAb, IgGI), W6/32 (HLA-A,B mAb, IgG2a),
RRIA (ICAM-1 mAb, IgGI), andX63(myeloma IgGI), have been
described(10). AllothermAbs were obtained through the 4thIn-
ternational Leukocyte workshop myeloid andlymphocyte panels.
Cell Lines.
￿
Previously established EBVtransformed cell lines
were maintained in RPMI 1640 medium supplemented with 20%
FCS, 2 mM glutamine, and 50 Ag/ml gentamicin (complete
medium) at 37°C in a humidified atmosphere of 5% CO2. Pa-
tients 2 and 14 areunrelated and hadnonconsanguineous, Cauca-
sian parents (2). Patient 2 had a severe phenotype and patient 14
a moderate phenotype. Both patients expressed grossly normal /3
subunit mRNA and precursor protein. Patients 1 and 15 inves-
tigated in the RNase protection assay had been shown to have
normal RNA andprecursor protein (24and unpublished observa-
tion, respectively). JY is a long-established EBVtransformed Bcell
line. Patient cell linesandtheC03healthy control line were trans-
formed in parallel with EBV (22, 24). Patient numbers refer to
reference24. COS cells areSV40 transformed monkey kidney cells.
Oligonucleotides.
￿
Oligonucleotides were synthesized on a 380B
DNA synthesizer (Applied Biosystems, Foster City, CA). Nomen-
clature was according to direction (sense ,QS, antisense #AS) fol-
lowed by the number of the first oligonucleotide 5' base in the
cDNA followed by mif encoding a mutation. Priming of cDNA
libraries: Patient 14, 17mer OAS1138 (5'-ATTAAGAATGCTTA
CAA-3'); Patient 2, 26mer OAS2468 (5'CCTCAAGAGCTGTG-
GCCAAGCCATG-3'). PCR: sense oligonucleotide encoding
BamHI site, 20mer ,i3S233 (5'-GGGGGATCCTGACTCCATTC-
3'); antisense 20merAAS780 (5'-000CACCCTCGGGTGCATCC-
3'). Site-directed mutagenesis: 41mer OS490m, (5'-TTGATGAC-
CTCAGAAATGT'CAAGAAGCCAGGTGGCGACCTG-3') . Se-
quencing: 20mers /3540, /35233, (35375, OS508, /35570, OS800,
(3AS203.
Ribonuclease Protection Assay.
￿
This wasperformedas described
(27). Total RNA was prepared from patient and normal EBV
transformed cells by the method of Chirgwin et al. (28) . To pre-
pare single-stranded RNA probes four fragments of -700 by
covering most of the coding region of the (3 subunit cDNA (Fig. 1
A) were each subclonedinto a plasmid vector (pT7T3 18u; Pharmacia
Fine Chemicals, Piscataway, NJ) that contained T7 andT3 promoters
flanking the polylinker. The plasmid template was transcribed in the
presence of 100 ACi of a-['2P] UTP (10 Ci/ml, 800Ci/mmol; New
EnglandNuclear, Boston, MA) and10 Uof T7 or T3 RNApoly-
merase (Pharmacia). The reaction mixture was incubated for 45
min at 37°C. The template was then digested with RNase-free
DNase (Boehringer Mannheim Biochemicals, Indianapolis, IN)and
unincorporated nucleotides removedby ammonium acetateprecipi-
tation. The probe was dissolved in hybridization buffer and 5 x
105 cpm added to 10 Ag of patient or control RNA andincubated
overnight at 45°C. The RNA was digested with ribonuclease A
and T1 for 45 mins at 30°C. In some experiments RNase UZ
(Boehringer Mannheim)andRNaseM(BethesdaResearch Labora-
tories, Gaithersburg,MD) (50 U/ml)were added. ProtectedRNA
was analyzed on adenaturing polyacrylamide/urea sequencing gel.
cDNA Library.
￿
Patient mRNA wasobtained from totalRNA
(preparedas above)by passingthrough an obgo(dT)-cellulose type
3 column (Collaborative Research Inc., Lexington, MA). The
cDNA was synthesized by the method of Gubler and Hoffman
(29) using a specific (3 antisense oligonucleotide as a primer and
avian myeloblastosis reversetranscriptase (24 units/A1;Life Sciences,
St . Petersburg, FL). Second strand synthesis was achieved usingDNAPblymerase I (Escherichia colt) (New England Biolabs, Beverly,
MA), and RNase H (Boehringer Mannheim). The cDNA was
ligated to Xgt10 (Stratagene, La Jolla, CA). 5 x 10' colonies were
screened with a nick-translated BamHI/EcoRI fragment of the /3
subunit cDNA. Aftertwo rounds ofplaque purification thecDNA
clones were subcloned into pGem7 (Promega Biotech, Madison,
WI) using the EcoRI cloning site.
Taq Pblymerase Reaction.
￿
This wasperformedas described (30).
First strand synthesis with reverse transcriptase using a 20meran-
tisense oligonucleotide(3 AS780 as aprimer wasperformed on 15
kg of total RNA from patient 14. A 20mer senseoligonucleotide
flS233 encoding the BamHI site was then added together with
5 U of Taq polymerase (5 U/Al; U.S. Biochemical Corp., Cleve-
land, OH).35 cycles ofdenaturation (94°C, 60 s), annealing(37°C,
2 min), and polymerization (68°C, 3 min) were undertaken with
a further 5 UofTaq polymerase added after the 25th cycle. After
the35th cycle the mixture was incubated at 68°C for 10 min. Of
the reaction mixture, 1/10th was analyzed on a 1% agarose gel
to confirm the presence of theamplifiedcDNA fragment. The re-
mainder of themixture wasblunt ended with the large fragment
of E. coli DNApolymerase I, heated to 70°C for 15 min, digested
with BamH1, and the 550 by band excised from a low melting
pointagarosegel. TheDNA was subclonedinto pGem7using the
BamHIandSmal cloning sites. CompetentJM83E.coliwere trans-
formed and plasmids containing the correct size insert were se-
quenced.
Generation ofMutant and Revertant Forms ofR Subunit cDNA in
pCDM8: (a) Patient 14. The mutation foundinpatient 14 was in-
troduced by site-directed mutagenesis (31-33) into the wild-type
(3 subunit cDNA cloned into pCDM8 (34), usingoligonucleotide
,3S490m which encoded the single base pair substitution as well
as a silent mutation which erased the unique Bsu36 I site. Two
tests confirmedthat defective expression wasdue to the mutation,
and not to an incidental change in the plasmid. First, a fragment
bounded by a vector EcoRI site upstream of the 5' untranslated
region and the internal EcoRI site at 965 by was sequenced after
site-directedmutagenesis to confirmthat no other substitution had
occurred. Second, the mutant ,l3 cDNA in pCDM8 was reverted
to wild type by subcloning a 1.0 kb wild-type EcoRl fragment
into the mutant (3.
(b) Patient2.
￿
Themutation present in thepatient 2 cDNA was
introduced into the wild-type (3 subunit cDNA by exchanging a
530-bp Bsu36I/BstEII restriction fragment (nucleotides 500-1,030).
This 530-bp region was sequenced to confirmthat it encoded only
oneaminoacid substitution. The mutant was reverted to wild type
by subcloning thewild-typeBsu361/BstEIIfragment back into the
patient 2 mutant a subunit cDNA.
Expression ofMutant Forms ofLFA-1.
￿
Wild-type, mutant, and
revertant forms of the (3 subunit were expressed in COS cells by
co-transfection with thewild-typea subunit ofLFA-1 by DEAE-
Dextrantransfection (35) using12 pg ofeach oftheaand ,Q subunits
cDNAs.3 d aftertransfection thecellswere detached with 10 mM
EDTA in HBSS and then either prepared forflow cytometric anal-
ysis, "I labeling, or binding to ICAM-1-coated plates.
Flow Cytometric Analysis.
￿
Immunofluorescence flow cytometry
was performed on an EPICS V analyzer after staining cells with
mAb-containing supernatants or a 1/200 dilution of ascites fol-
lowed by FITC-conjugated anti-mouse antibody (Zymed Labora-
tories, San Francisco, CA) as described (36). Cells were analyzed
either unfixed or fixed in 1% paraformaldehyde.
Surface Iodination.
￿
1251 labeling of COS cells was performed as
described (26). COS cells were harvested, labeled with I'll (0.5
mCi of 100 mCi/ml Na 1251; Amersham Corp., Arlington Heights,
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IL) and lysed for 1 h in 1 ml of ice cold lysis buffer (10 mM Tris
pH 8.0, 0.15 M NaCl, I% TX-100, 1% hemoglobin, 1 mM io-
doacetamide, 1 mM PMSF, 0.25 TIU/ml Aprotinin, 0.025%
N2N3). After pelleting the nuclei, the lysate was precleared over-
night with 100 Al of packed human IgG coupled to Sepharose.
The lysate was then immunoprecipitated with 20 Al ofpacked mAb
bound to Sepharose for 2 h. The beads were washed three times
in 25 mM Tris pH 8.0, 150 mM NaCl, 0.1% TX-100, twice in
25 mM Tris pH 8.0, 150mM NaCl, and once in 50 mM Tris, pH
8.0, and analyzed by SDS-PAGE under reducing conditions fol-
lowed by autoradiography.
Biosynthetic Labeling.
￿
COScellstransfected with either thewild-
type /3 subunit, patient 2 mutant / .3 subunit or patient 14 mutant
(3 subunit were pulsed-labeled at a density of 2-4 x 105 cells/10
cm dish for 1 h at 37°C with 500 ACi of [35S]cysteine/methio-
nine in cysteine/methionine-free complete media containing 5%
dialyzed FCS. The cells were chased for either 0, 2, 4, or 8 h in
media containing 250 pig/ml cysteine and 100hg/mlmethionine.
Cells were harvested with HBSS/10 mM EDTA and lysed as de-
scribed above for surface iodination. Cell lysates were precleared
overnight with 5 Al normal rabbit serumand 50 Al packed protein
A-Sepharose, then immunoprecipitated for 2 h with either 2 Al
normal rabbit serum or 2 Al rabbit anti-denatured /3 subunit serum
(24) and 10 Al packed protein A-Sepharose. Immunoprecipitates
were washed as described in the preceding section and subjected
to 7% SDS-PAGE and fluorography.
Purification of ICAM-1.
￿
The procedure was modified from
Marlin and Springer (7). ICAM-1 was purified by affinity chroma-
tography on RRl/1-Sepharose from lysates of hairy cell leukemia
spleens as described (34) .
Binding of Transfctants to ICAM-1.
￿
Purified ICAM-1 was ab-
sorbed to wells of a PVC microtiter plate (Flow Laboratories,
McLean, VA) as described (10) at a previously determined con-
centration of 4,000 sites/Am'. ICAM-1 site numbers were deter-
mined using saturating amounts of '251 anti-ICAM-1 mAb and
calculated assuming bivalent binding of the mAb. Adherence of
10' Na251CrO4-labeled transfectants to ICAM-1-coated plates was
assayed as described (34).
DNA Sequencing.
￿
All sequencing was performed on double-
stranded DNAby thedideoxychaintermination method (37) using
the protocol recommended by the manufacturer for the use of
modified T7 DNA polymerase (Sequenase; US Biochemical Corp.).
SecondaryStructure.
￿
Predictions used the UniversityofWisconsin
genetics computing group software (38) .
Results
Screening Strategy.
￿
The strategy of Myers et al. (39) was
used to define sites of mutations in patient 0 subunit RNA.
Radiolabeled antisense RNAprobes spanning essentially the
entire (3 subunit coding region (Fig. 1 A) were hybridized
with patient total RNA and sites of mismatch, as evidenced
by lack of protection from RNase digestion, were defined
by gelelectrophoresis. This method has thedisadvantage that
only certain mismatched bases are recognized by the avail-
able RNases, and thus only a subset of mutant alleles will
be identified by this technique. However, it has the advan-
tage that identification of the region of mismatch simplifies
subsequent nucleotide sequence analysis. Of four patients
studied initially, two were found to have sites ofcleavage notFigure 1 .
￿
RNase protection assay. (A) Restriction fragments of the
0 subunit cDNA were subcloned into the plasmid pT7/T3 18U
which contains diametrically opposed T3 and T7 promoters. Probes
1-4 span the entire coding region apart from a 42-bp region between
the two Smal sites. Probe 2A is a subfragment of Probe 2 . B,
BamHl ; A, Apal; E, EcoRl ; S, Smal ; H, HgiA1 . (B) Single-stranded,
radiolabeled probe 2 RNA (lane 1) or probe 2A RNA (lane 6) were
hybridized overnight to total RNA from JY (lanes 2 and 7), a con-
trol EBVtransformed B cell line C03 (lanes 3 and 8), an EBV
transformed B cell line derived from patient 14 (lanes 4 and 9), and
tRNA as a control for complete digestion (lanes 3 and 10) . RNA
was digested with ribonucleases A and T1 and protected RNA ana-
lyzed by gel electrophoresis. (C) Single-stranded, radiolabeled probe 2
RNA (lane 1) was hybridized overnight to total RNA from JY (lane
2), COS (lane 3), EBVtransformed B cells from patient 15 (lane 4),
EBVtransformed B cells from patient 1 (lane 5), and EBV
transformed B cells from patient 2 (lane 6) . RNA protected after
digestion with ribonuclease was analyzed by gel electrophoresis.
present in controls . We therefore focused on these two pa-
tients, numbers 14 and 2 .
Patient 14 .
￿
In patient 14, probe 2 was partially digested
to two bands of 280 by and 450 by which together added
up to the size of the fully protected probe (Fig . 1 B, lane
4) . This pattern was confirmed by using the shorter probe
2A, which also gave a 280-bp fragment and localized the de-
fect to the region of nucleotide 513 (Fig. 1 B, lane 9) . The
probe contained vector sequences and thus protection with
wild-type RNA yielded a 303-bp fragment (Fig . 1 B, lanes
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Figure 2 .
￿
Sequencing of mutations in patient-derived cDNA
clones . (A) Patient 14 . Using total RNA as a template and oligonu-
cleotides OS233 and (3AS780 as primers, a 547-bp fragment of the 0
subunit cDNA between 233 and 780 by was amplified by PCR, sub-
cloned into pGEM7, and 10 plasmids were sequenced in the region
of the putative point mutation. Representative sequencing ladders are
shown for the five patient clones that were wild type in this region
and the five clones that encoded substitution of a T for a C at
nucleotide 517, which changes a leucine to a proline at amino acid
149 . (B) Patient 2. A representative sequencing ladder for the five in-
dependent 13 subunit cDNA clones derived from patient 2 that con-
tain a substitution of a G for an A at nucleotide 577 which changes
a glycine to an arginine at amino acid 169 is compared to a wild-type
sequencing ladder.
7 and 8) ; note equal amounts of the 303 and 280 by frag-
ments were yielded by patient 14RNA (Fig. 1 B, lane 9) .
A classical Xgt10 library was constructed from patient 14
mRNA after specific priming with an antisense oligonucle-
otide at nucleotide 1188 of the (3 subunit . Six independent,
hybridizing clones were plaque purified, subcloned, and se-
quenced in the region of nucleotide 513 . In one clone a sub-
stitution of a T for a C was found at nucleotide 517; the
other five clones were ofwild-type sequence . One ofthe clones
with the wild-type sequence at nucleotide 517 was sequenced
from the ATG initiation codon to the internal EcoRI site
at nucleotide position 965 ; no deviations from wild type were
observed .Mock
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Mutation
L149P
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Mutation
G1699
Patient 2
Revertant
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Flow cytometric analysis of wild-type, mutant, and rever-
tant (3 subunit cDNAs expressed in COS cells. The indicated 0
subunit cDNAs in pCDM8 were analyzed for their ability to support
expression of LFA-1 in COS cells after co-transfection with the a
subunit of LFA-1. Mock transfectants in which no DNA was used in
the transfection procedure were used as negative controls and wild
type 0 subunit as a positive control. X63, Control antibody; TSl/22,
anti-LFA-1 a mAb; TS1/18, anti-a mAb.
To further study the mutation, patient 14 mRNA was sub-
jected to reverse transcriptase and polymerase chainreaction
to amplify a 548-bp fragment encoding the region of in-
terest. 10 plasmids containingthe correct size insert were se-
quenced. Five were of wild type and five encoded the T to
C transitionat nucleotide 517 (Fig. 2 A). This mutation results
in the substitution of a leucine for a proline at amino acid
149. Thus one of the 0 subunit alleles in patient 14 contains
a mutation at nucleotide 517. The otherallele appears normal
in the region 5' to nucleotide 965, and we hypothesize a mu-
tation 3' to nucleotide 965 .
Patient 2.
￿
With the addition of RNase M and U2 into
the RNase assay digestion mixture two bands of 370 and
330 by appeared, suggesting a mismatch in the region of
nucleotide 535 to 635 (Fig. 1 C, lane 6). No full-length band
was seen. A full-length classical cDNA library was constructed
in Xgt10 from patient RNA, priming first strand synthesis
with an antisense oligonucleotide at position 2468 in the 3'
untranslated region. Five independent hybridizing colonies
whose inserts extended beyond nucleotide 500 were plaque
purified, subcloned, and sequenced in the region of interest.
In each of the five clones a base pair substitution o£ a G for
an A was observed at nucleotide 577 which resulted in the
substitution of a glycine for an arginine at amino acid 169
(Fig. 2 B). These results, together with lack of a wild-type
sized fragment in protection assays with probe 2, suggest ei-
ther homozygosity of this allele or presence of this allele to-
gether with a second allele which does not give rise to a 0
subunit transcript.
Expression of Patient Mutations in COS Cells.
￿
Previous
studies have shown that LFA-1 is expressed and functionally
active in binding ICAM-1 in COS cells which are cotrans-
fected with expression vectors containing the a and (3 subunit
cDNAs (40). To examine the functional consequence of the
base substitutions, and confirm that they were not normal
polymorphisms, they were introduced into the wild type (3
subunit cDNA in the mammalian expression vector pCDM8.
For the patient 14 mutation, site-directed mutagenesis was
used; for the patient 2 mutation, a 530-bp fragment from
the patient cDNA was subcloned into wild-type i3 subunit
cDNA. The mutated forms of the ,Q subunit were expressed
in COS cells by co-transfection with wild type LFA-1 a. Cell
surface expression was determined by immunofluorescence
flow cytometry (Fig. 3). Expression of wild-type LFA1 gave
a high mean fluorescence with 65% ofcellspositive for both
LFA1 a subunit (TS1/22 mAb) and0 subunit (TSl/18 mAb)
(Fig. 3, B compared to mock transfected cells in A). A low
level of expression of the LFA-1 a/,Q heterodimer with the
a subunit containing the patient 14 mutation was detected
with TS1/22 (anti-LFAIci); however, no expression was seen
when the same cells were stained with TS1/18 (anti-0) (Fig.
3, panel 3C). COS cells transfected with the a subunit of
LFA1 and the (3 subunit containing the patient 2 mutation
showed very low levels of LFA1 expression with TS1/22 and
no expression with TS1/18 (Fig. 3, E) . Very inefficient ex-
pression of the a subunit of LFA-1 was seen in cells trans-
fected with the a subunit ofLFA1 alone (datanot shown; 40).
To confirm that the mutations defined in patients were
the cause of the defective expression, and that incidental mu-
tations had not been introduced, the mutated /3 subunits in
pCDM8 were reverted to wild type by exchanging wild-type
fragments with the mutated region and the mutated region
was sequenced. Both the patient 14 and the patient 2 rever-
tants expressed normally as assessed by staining with both
TS1/22 and TS1/18 (Fig. 3, D and F, respectively).
Analysis ofExpression ofthe Patient 14 Mutant LFA-1 Using
a Panel of Anti-LFA-1 Antibodies. To further explore the
differential staining ofCOS cells transfected with thea subunit
of LFA-1 and the (3 subunit encoding the patient 14 muta-
tion noted above, transfectants expressing the patient 14 mu-
tant LFA1 were screened with two anti-LFA1 a and six anti-a
mAbs (Fig. 4). Both anti-LFA-1 a mAbs stained the patient
14 mutant COS cell transfectants (Fig. 4 B, panels 1, 2), how-
ever expression was significantly lower than that observed
for wild type transfectants (Fig. 4 A, panels 1, 2) . Three of
the anti-# mAbs gave the same negative or weak staining
pattern as TS1/18 (Fig. 4 B, panels 3-5, 8). Expression of
the mutant (3 subunit was observed with two anti-/3 mAbs
which stained with the same mean fluorescence as the anti-
LFA-1 a mAbs (Fig. 4 B, panels 6, 7) . The a subunit can
be expressed in COS cells without an appropriate leukocyte
integrin a subunit, however not all anti-# subunit mAb epi-
topes remain structurally intact (40, 41; Fig. 4 C). No ex-
pression of the patient 14 mutant 0 subunit was observed
when transfected into COS cells in the absence of the LFA1
a subunit (Fig. 4 D). Thus in patient 14 both the a subunit
and the mutant a subunit were expressed on the surface of1 .
￿
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Figure 4.
￿
Flow cytometric analysis of COS cells transfected with (A) wild-type LFA-1 a and (3 subunits, (B) wild-type LFA-1 a and patient
14 mutant S subunits, (C) wild-type /3 subunit alone and (D) patient 14 mutant Q subunit alone. Transfected COS cells were labeled with ei-
ther the indicated anti-~3 and anti-LFA-1 a subunit mAbs (thick lines) or a nonbinding control mAb X63 (thin lines) .
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Flow cytometric analysis of patient 14 EBVtransformed B cell lines. Patient 14 EBVtransformed B cells were labeled with either the
indicated anti-/3 and anti-LFA-1 a subunit mAbs (thick lines) or a nonbinding control mAb X63 (thin lines).
COS cells but with considerably reduced expression and, in
the case of the a subunit, loss of the epitope for a number
of anti-,Q mAbs.
Expression of LFA1 on the surface of the patient 14 EBV
transformed B cells was also investigated usinga similar panel
of antibodies. These cells had low levels of expression of LFA-1
when stained with the five anti-LFA-1 a subunit mAbs and
compared with a nonbinding control antibody, consistent with
the moderate phenotype of this patient (Fig. 5, H-L) . No
expression was observed with TSl/18 (Fig. 5 A) or two other
anti-# mAbs (Fig. 5, B and F) . In contrast, a low level of
expression was observed with four other anti-/3 mAbs (Fig.
5, C, D, E and G). One anti-(3 mAb that stained the patient
14 EBVtransformed B cells showed no reactivity with pa-
tient 14 mutant COS cell transfectants (Fig. 5 G compared
with Fig. 4 B, panel 8). Positive staining with all the mAbs
tested was confirmed by staining the C03 control EBV cell
line (data not shown).
Biosynthesis of Normal and Mutant 0 Subunits.
￿
Deficiency
in surface expression of the ,(3 subunits of patients 2 and 14
could be because they were more rapidly degraded than the
wild-type (3 subunit or because they associated less efficiently
than wild-type 0 subunit with the a subunit. Previous ex-
periments on the biosynthesis of mutant0 subunits have been
carried out in patient lymphoblastoid cell lines(24). The half-
lives of some patient /3 subunits were shorter than wild-type,
but this may have been because association of a with wild-
type ,(3 resulted in transport to the cell surface and a longer
half-life. The COS cell transfection system provided the op-
portunity to study a subunit half-life in the absence of the
a subunit. COS cells transfected with either wild-type
a subunit or mutant a subunits were pulse-labeled with
I35Sjcysteine/methionine and chased for varying times. An
immature (3 subunit of -89 kD was immunoprecipitated
from pulse-labeled cells expressing the wild-typed subunit
(Fig. 6, lane 4). No change in mobility was observed upon
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chase indicating that the (3 subunit is not being processed
to the higher molecular weight, mature form in the absence
of the LFA-1 ca subunit (Fig. 6, lanes 10, 16, 22) . As has
been previously demonstrated (24), patients 2 (Fig. 6, lane
S) and 14 (Fig. 6, lane 6) synthesized precursors of approxi-
mately normal size. In both patients, the precursor was still
readily detectable after an 8-h chase. Indeed, there was no
significant difference in the amount ofasubunit precipitated
from cells expressing either wild-type or mutant /3 subunits
after a 2-, 4-, or 8-h chase. These results indicate that the
mutant /3 subunits are not being degraded more rapidly than
the wild-type (3 subunit.
Analysis ofthe Functional Capacity ofthe Patient 14 Mutant
LFA-1. To investigate if the patient 14 mutant LFA-1 could
bind to its counter-receptor we measured binding of COS
cells transfected with wild type, mutant and revertant LFA-1
to microtiter wells coated with ICAM-1 (Fig. 7). In the pres-
ence ofW6/32 as a nonblocking antibody we observed 10%
binding to ICAM-1 for wild-type and revertant transfectants
compared with a background of 1-2% with mock transfec-
tants or binding to human serum albumin (HSA). No binding
was seen with COS cells transfected with the patient 14 mu-
tant LFA-1. Binding of the wild-type and revertant transfec-
tantswas specific as shown by inhibition with the anti-ICAM-1
antibody RR1/1. Testing of the CLB54 mAb, one of the
anti-O mAb that stains patient 14 COS cell transfectants,
showed that it is able to block interaction ofwild-type LFA
1 with ICAM-1.
Immunoprecipitation of 1251 Surface-Labeled Wild-Type and Pa-
tient 14 COS Cell Transfectants. To investigate if the a and
(3 subunits of patient 14 LFA1 were associated on the cell
surface, COS cells transfected with wild-type and mutant
LFA-1 were labeled with 1251 and cell lysates immunoprecip-
itated with anti-LFA-1 mAbs bound to Sepharose. In wild-
type transfectants, the TS1/22 anti-ca mAb and TS1/18 anti-
0 mAb each precipitated the mature forms of the a and/3 subunits ofLEA-1 at 180 and 95 kD, respectively (Fig . 8,
lanes 2 and 3) . In cells transfected with the LFA-1 a subunit
and the /3 subunit containing the patient 14 mutation, TS1/22
mAb precipitated an a but no 0 subunit (Fig . 8, lane S),
Figure 7.
￿
Binding ofCOS cells expressing wild-type, patient 14
mutant and revertant LFA-1 to ICAM-1 . 5'Cr-labeled transfectants
were bound to ICAM-1-coated plates in the presence of W6/32,
anti-HLA A/13; TS1/22, anti-LFA-1; CLB54, anti-LFA-1 ; RRI/1, anti-
ICAM-1; or bound to human serum albumin (HSA)-coated plates.
342 Mutations in Leukocyte Adhesion Deficiency
Figure 6 .
￿
Biosynthesis of normal
and mutant 0 subunits . COS cells
transfected with either the wild-type
a subunit, patient 2 mutant 0
subunit, or patient 14 mutant 0
subunit were pulse labeled with
135S]
cysteine/methionine for 1 h and then
chased for either 0, 2, 4, or 8 h as in-
dicated. Lysates were immunoprecipi-
tated with either normal rabbit serum
(NRS) or anti-O subunit serum as in-
dicated and subjected to reducing SDS
7% PAGE and fluorography.
suggesting that thea and (3 subunits were either not associated
or that the association was weak and the subunits became
dissociated during cell lysis. The a subunit appeared smaller
than the wild type a subunit suggesting that it may not have
been fully processed . TS1/18 anti-/3 mAb did not precipitate
anyLFA1 from the mutant cells, as would be expected from
the flow cytometry data and its previously described inability
to precipitate the (3 subunit in its unassociated state (22) .
Discussion
We have analyzed the molecular basis ofLAD in two pa-
tients, one with a moderate clinical phenotype (patient 14)
and one ofthe severe phenotype (patient 2) . The RNase pro-
tection assay was used to localize possible sites of base pair
mismatch . When examining cleavage ofRNA:RNA duplexes
with RNase A, Myers et al . (39) found that, depending on
the surrounding bases in the probe, a C:A (probe:template)
mismatch as in patient 2 cleaved in all cases tested, a A:C
mismatch as in patient 14 cleaved in some cases, whereas a
G:U mismatch never cleaved . This may explain why mis-
matches were detected in only two of the patients that were
examined. In these patients, distinct defects were detected
that mapped to adjacent regions of the /3 subunit cDNA .
Sequencing ofcDNA clones from patient 2 in the region
indicated by the RNase assay revealed a base pair substitu-
tion in all five clones examined, resulting in the substitution
of a glycine for an arginine. Together with the total loss of
protection of the full-length RNA in the RNase assay thisFigure 8 .
￿
Immunoprecipita-
tion of wild-type and patient
14 mutant LFA-1 expressed in
COS cells . Lysates of 1251-la
beled COS cells co-transfected
with wild-type LFA-1 a and
either wild type 0 subunit or
the 0 subunit containing the
patient 14 mutation were im-
munoprecipitated with human
Ig-Sepharose, anti-LFA-1 a
subunit mAb-Sepharose or
anti-S subunit mAb-Sepharose
as indicated . Molecular weight
standards are marked .
suggests that only one allele is expressed in this patient . In
patient 14, in half the clones sequenced there was a single
base pair substitution at nucleotide 517 that would result in
the substitution ofa proline for a leucine . In one of the clones
which did not have this substitution no deviations from wild
type were seen in the 5' end of the cDNA up to the internal
EcoRI site, suggesting that the second allele in patient 14
carried a mutation in thecDNA 3' to the internal EcoRI site.
Both mutant (3 subunits were deficient compared with wild
type in ability to be expressed in association with thea subunit
on the surface of transfected COS cells. This was not due
to decreased half-life of the mutant /3 subunit precursors as
shown by pulse-chase experiments . Therefore, the defect is
due to inefficient association of the mutant (3 subunits with
thea subunit ; previous biosynthesis experiments have demon-
strated a lack of formation of an a/a complex in the en-
doplasmic reticulum of patient cells (24) . No expression of
LFA-1 was observed following cotransfection of thea subunit
containing the patient 2 mutation with wild-type LFA-1 a
subunit . This lack of expression is consistent with the severe
clinical phenotype and lack of expression on the leukocytes
ofthis patient . In contrast to patient 2, diminished although
clearly detectable expression was observed following co-
transfection of the a subunit containing the patient 14 mu-
tation with the wild-typeLFA1 a subunit . With the majority
of anti-(3 subunit mAbs no expression was observed; how-
ever, two anti-/3mAbs detected expression comparable to that
seen with the anti-LFA-1 a mAbs . The a subunit of LFA-1
cannot be efficiently expressed unless it first associates with
the /3 subunit since it is expressed very poorly when trans-
fected alone into COS cells (40) . This suggests that in COS
cells transfected with the (3 subunit containing the patient
14 mutation, association between the mutant (3 subunit and
the wild-typea subunit must be taking place. However, this
association is defective. The a subunit immunoprecipitated
from the transfectants expressing the mutant LFA-1 appeared
to be smaller than that precipitated from the wild-type trans-
fectants, suggesting that it had not undergone full carbohy-
drate processing. Expression of both subunits was impaired
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and theS subunit was not immunoprecipitated with the anti-
LFA1 a mAb. Dissociation of the two subunits could have
occurred either during transport of the protein to the cell
surface, on the cell surface, or during preparation of the cell
lysates . If dissociation occurred on the cell surface this might
explain the loss of reactivity of some of the anti-/3 mAbs in
immunofluorescence flow cytometry, since the epitope for
some anti-a antibodies is dependent on a/a association . Al-
ternatively, a//3 complexes may be present on the cell sur-
face but the mutation may directly alter the epitope recog-
nized by certain (3 mAb or indirectly disrupt conformation .
Chou-Fasman prediction of secondary structure and the
Garnier-Osguthorpe-Robson prediction of antigenicity sug-
gest that the region of the mutation in patient 14 is an a
helix of high antigenicity in which a turn is introduced by
the substitution of the proline for the leucine at position 149 .
The inability of the patient 14 mutant LFA-1 transfectants
to bind to ICAM-1-coated plates is most readily explained
by the diminished level of expression of LFA-1 compared to
wild type. We have found that in EBVtransformed B cells
the level of LFA-1 expression has a marked effect on binding
(34) . A contributory factor may be the altered structure and
conformation of the a and a subunits on the cell surface.
Expression in COS cells of the Leu149Pro mutation was
much higher than in the EBVtransformed B cells from pa-
tient 14 . This is probably because the COS cell system is de-
signed to overexpress and therefore drives the weak associa-
tion between thea subunit and the mutateda subunit. Patient
14 was of the moderately deficient phenotype, having suc-
cumbed to septicemia in early adulthood. It is not clear
whether the Leu149Pro mutation or the other allele expressed
in patient 14 is responsible for the moderate phenotype. The
other allele may account for reactivity of the GRF1 /3 mAb
with the patient 14 cell line and not with COS cells trans-
fected with the Leu149Pro mutant R subunit .
The two mutations that we have identified, which are lo-
cated within 20 amino acids of each other, define a region
of crucial importance for a/(3 association in the leukocyte
integrins in vivo, although clearly Leu149Pro gives a moderate
phenotype in COS cells in vitro. This appears not to be the
only region of 0 important in association with a, as evi-
denced by the other allele in patient 14 which appears to have
a mutation somewhere between residues 277 and 747 . How-
ever, the two mutated residues we have defined are of partic-
ular interest . They are conserved in all known integrin /3
subunits (Fig. 9), including 03, the /31 subunits of human,
chicken, and Xenopus, and the PS antigens of Drosophila .
These two residues lie within a highly conserved region of
241 amino acids in the a subunit (20) . In addition, both amino
acids are in the 63 amino acid region that in the (33 subunit
of platelet gpIIb/IIIa crosslinks to RGD peptides and thus
appears to be a ligand binding site (Fig . 9) . The close struc-
tural and functional relationships between the members of
the integrin superfamily suggests that this region ofthe leu-
kocyte integrin (3 subunit ((32) may also be involved in ligand
binding. Disruption of association with a by the mutations
described here suggests that this region may be one wherethea and0 subunits come together to form a ligand-binding
pocket .
We have recently shown that stable expression of LFA1
in EBVtransformed B cells from LAD patients with a va-
riety of patterns of defect can be recovered following trans-
Cell. 48:549 .
344
￿
Mutations in Leukocyte Adhesion Deficiency
Figure 9.
￿
Schematic representation of
the # subunit showing the location of
the mutations in relation to the highly
conserved region and the putative RGD
binding region in platelet gpIII2 . The se-
quences of the three integrin 0 chains in
the region to which RGD peptides cross-
link is from D'Souza et al . (20) . The
original description of the sequences of
02, (33, ,0,, and the PS integrin 13 subunit
are found in (16-19, 42-43), respectively.
fectionwith a normal (3 subunit gene subclonedinto amam-
malian expression vector (34) . Together with the present study,
this suggests that even in patients with LAD that express
a R subunit that migrates normally in SDS-PAGE, that amu-
tation in this protein is the cause of the disease.
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